Headquartered in Wilmington, DE Fiscal year ends January NYSE: PHR phreesia.com
Phreesia is a patient activation platform that provides digital solutions to healthcare providers, life sciences companies and other organizations to help patients take a more active role in their care. Founded in 2005 and operating as an all-remote company, Phreesia enabled more than 180 million patient visits in 2025, representing approximately one in six visits across the United States. The company generates revenue through three segments: Subscription and Related Services (SaaS fees from healthcare provider clients), Payment Solutions (payment processing and patient financing through its AccessOne acquisition), and Network Solutions (engagement tools for life sciences companies including PatientConnect and ProviderConnect). Phreesia's platform encompasses patient intake, outreach, education, eligibility and benefits verification, collections, and clinical workflows. The company is increasingly integrating artificial intelligence across its products, including PlanMatch for billing plan selection and VoiceAI for workflow automation. Phreesia serves 4,744 average healthcare services clients and maintains a credit facility with Capital One. Updated
Pre-Market Stock Futures: Futures are trading higher on the heels of the third straight day of stock declines, and there is growing apprehension that yields will go even higher and that inflation…
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Yesterday we were watching whether Phreesia’s path to profitability would accelerate after two consecutive near-breakeven quarters. They delivered solid earnings after the bell on December 8, reporting EPS of $0.31. Profitability Arrives,…
William Temple Phreesia is a patient activation platform that provides digital solutions to healthcare providers, life sciences companies and other organizations to help patients take a more active role in their care.
The Wall Street consensus 12-month price target for PHR is $14.07.
